The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients

This study has been withdrawn prior to enrollment.
(Terminated by Sponsor)
Sponsor:
Collaborator:
The Medicines Company
Information provided by (Responsible Party):
Stephan A. Mayer, Columbia University
ClinicalTrials.gov Identifier:
NCT01526876
First received: February 2, 2012
Last updated: February 26, 2013
Last verified: February 2013
  Purpose

Patients with acute brain injury are at risk for complications such as increased pressure in the brain (intracranial pressure, ICP), decreased blood flow, bleeding, and brain swelling (cerebral edema). Several studies have suggested that high blood pressure is associated with a worsening outcome possibly due to an increased rate of continued bleeding or rebleeding, as well as increased brain swelling (cerebral edema). High systemic (body) blood pressure (SBP) may also increase the risk of ongoing bleeding. Therefore lowering the blood pressure (BP) is critical, as continued bleeding occurs most frequently in patients with high BP.

Clevidipine Butyrate (Cleviprex) is a new medication approved by the FDA for the treatment of acute high blood pressure (hypertension). Cleviprex is given through an intravenous line (IV) and has the benefit of being faster acting and easier to control adjustments than other drugs used to treat high BP. Patients who have an acute brain injury and who have severe high BP may benefit from this faster acting medication.

For this study, eligible patients, 18 yrs of age or older, will have been admitted to the Neurocritical care unit within 24 hours after their brain injury, who have high systemic (body) SBP. The treating physicians will have already had multimodality brain monitoring placed for clinical management of the patient (standard care).

The investigators will use Cleviprex to lower their SBP and record brain pressure and brain blood flow measurements from the multimodality monitoring. Due to the severity of their brain injury most of the patients eligible for the study will be unable to provide consent. Informed consent will be sought from a surrogate (family member, spouse or close friend) according to CUMC guidelines.

Cleviprex is fast acting and effects are seen in about 90 seconds. The medication will be started at a low rate, and if the SBP still needs lowering, the dose increased every 90 seconds until the maximum FDA approved dose is reached. If the SBP is still high, another medication used to treat high blood pressure will be added (Cardene or labetolol).

Once the SBP is lowered and is stable, the Cleviprex will be continued for 6 hours. As part of standard care, patients have their blood pressure monitored continuously. After 6 hours the treating physician will make a determination to continue clinical management with cleviprex or another antihypertensive medication.


Condition Intervention Phase
Hypertension
Drug: clevidipine butyrate
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Reduction in blood pressure [ Time Frame: Up to 24 hours from the start of clevidipine infusion ] [ Designated as safety issue: Yes ]
    Systemic Blood Pressure will be monitored every minute for the first 30 mins, at 45 and 6 mins and then hourly for 6 hours of treatment. ICP will be monitored every 5 minutes from start of infusion up to 6 hours of treatment


Secondary Outcome Measures:
  • "Time to target" (below the CCP threshold and Percent time within the target CCP range) [ Time Frame: Up to 24 hours from the start of infusion ] [ Designated as safety issue: Yes ]
    Will be looking at the "Time to target" (below the CCP threshold and Percent time within the target CCP range) to assess whether clevidipine is safe and effective for rapidly controlling blood pressure to achieve desired cerebral perfusion pressure (CCP).


Enrollment: 0
Study Start Date: November 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm drug study
The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
Drug: clevidipine butyrate
intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
Other Name: Cleviprex

Detailed Description:

This is an open-label, single arm, single center study in patients with hypertension in the setting of an acute brain injury. Approximately 15 patients admitted to the Columbia University Neurocritical Care Unit with intracerebral hemorrhage, subarachnoid hemorrhage or traumatic brain injury who are hypertensive and have neuromonitoring probes placed in the course of standard clinical management will be enrolled over a 10-12 month period. Patients must be hypertensive (SBP > 180mmHg), or have an elevated cerebral perfusion pressure (CPP, above 100 mm Hg) and the decision has been made by the ICU team to initiate an infusion of clevidipine to maintain CPP within a target range of 70-90 mm Hg and SBP between 120-180mmHg.

Due to the decreased level of consciousness from their injury, the majority of patients will be unable to provide consent. Informed consent will be sought from a surrogate according to Columbia University Medical Center (CUMC) guidelines (See section 8-Informed Consent Process).

Clevidipine infusion will be used to treat hypertension within the first 24 hours after injury. Multi-modality brain monitoring will have been placed as standard care.

Clevidipine will be infused at an initial rate of 2.0 mg/h for the first 90 seconds and titrated to effect (CPP target range of 70-90 mm Hg) by either doubling or reducing the dose by 50% every 90 seconds (with dose ranging 0-32mg/h of continuous IV infusion).

At the end of 6 hours clevidipine treatment, the treating physician will make a determination to continue clinical management with clevidipine or change to another antihypertensive medication.

Patients will be monitored at 24 hours after infusion for liver function, triglycerides and lipase.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Coma (GCS less than or equal to 8) due to any cause
  2. Male and Female patients > 18 years.
  3. Mechanically ventilated
  4. Functional multimodality neuromonitoring bundle (ICP monitor, Hemedex, Licox, and microdialysis) placed in the course of routine clinical management
  5. Patient is hypertensive at the time of enrollment (CPP >100 mm Hg and/or SBP >180mmHg) and the decision has been made to start clevidipine butyrate in order to maintain CPP within 70-90 mm Hg and/or SBP <180mmHg
  6. Patient has a minimum of 60 min of baseline brain multimodality monitoring prior to initiation of clevidipine -

Exclusion Criteria:

  1. Absence of negative pregnancy test in women of child-bearing potential.
  2. FiO2 >50%
  3. Unable to maintain stable sedative infusion rates for 4 hours
  4. Unable to maintain stable ventilator setting for 4 hours
  5. Unable to maintain stable insulin infusion rates for 4 hours
  6. Patient is currently receiving nicardipine infusion
  7. Allergy to soybean oil or lecithin
  8. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01526876

Sponsors and Collaborators
Columbia University
The Medicines Company
Investigators
Principal Investigator: Stephan A Mayer, MD Columbia University
  More Information

No publications provided

Responsible Party: Stephan A. Mayer, Professor of Neurology, Columbia University
ClinicalTrials.gov Identifier: NCT01526876     History of Changes
Other Study ID Numbers: AAAF4096
Study First Received: February 2, 2012
Last Updated: February 26, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Intracranial Pressure
Cerebral Perfusion Pressure
Clevidipine Butyrate

Additional relevant MeSH terms:
Hypertension
Brain Injuries
Vascular Diseases
Cardiovascular Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Clevidipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014